Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
December 10 2018 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced that it will host a
Research and Development Day focusing on the Company’s Factor VIIa
and Factor IX hemophilia programs on Tuesday, December 18, from
12:00-2:00 p.m. EST at the Lotte New York Palace.
Catalyst Biosciences' management team will provide an update on
the Company’s ongoing clinical development work with marzeptacog
alfa (activated) (MarzAA), a high potency engineered Factor VIIa
for the potential subcutaneous prophylactic treatment of hemophilia
A or B with inhibitors, and Factor IX, dalcinonacog alfa (DalcA,
formerly known as CB 2679d/ISU304) for the potential subcutaneous
prophylactic treatment of hemophilia B. The Company recently
announced updated positive interim data from its Phase 2/3 study of
MarzAA, which was presented at the 60th American Society of
Hematology (ASH) Annual Meeting & Exposition on December 1,
2018.
This event is intended for institutional investors, sell-side
analysts, investment bankers, and business development
professionals only. Please RSVP in advance if you plan to attend,
as space is limited. For those who are unable to attend in person,
a live webcast and replay of the event will be accessible here. If
you would like to ask a question during the live Q&A portion of
the event, please submit your request via email.
About Catalyst BiosciencesCatalyst is a
clinical-stage biopharmaceutical company developing novel medicines
to address hematology indications. Catalyst is focused on the field
of hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include statements
about the potential for marzeptacog alfa (activated) (MarzAA) to
provide prophylaxis therapy in patients with hemophilia A or B with
inhibitors, and for dalcinonacog alfa (DalcA, formerly known as CB
2679d/ISU304) to provide phophylaxis therapy in patients with
hemophilia B. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that the Company makes,
including, but not limited to, the risk that trials and studies may
be delayed and may not have satisfactory outcomes, that additional
human trials will not replicate the results from earlier trials,
that potential adverse effects may arise from the testing or use of
MarzAA or DalcA, including the generation of antibodies, which has
been observed in patients treated with DalcA, the risk that costs
required to develop or manufacture the Company’s products will be
higher than anticipated, competition and other factors that affect
our ability to establish collaborations on commercially reasonable
terms and other risks described in the “Risk Factors” section of
the Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2018 filed with the Securities and Exchange
Commission on November 1, 2018, and with other filings with the
Securities and Exchange Commission. The Company does not assume any
obligation to update any forward-looking statements, except as
required by law.
Contacts:Investors:Fletcher
Payne, CFOCatalyst Biosciences,
Inc.1.650.871.0761investors@catbio.com
Media:Josephine Belluardo, Ph.D.LifeSci Public
Relations1.646.751.4361jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024